SG10201604497UA - Molecular Diagnostic Test For Cancer - Google Patents
Molecular Diagnostic Test For CancerInfo
- Publication number
- SG10201604497UA SG10201604497UA SG10201604497UA SG10201604497UA SG10201604497UA SG 10201604497U A SG10201604497U A SG 10201604497UA SG 10201604497U A SG10201604497U A SG 10201604497UA SG 10201604497U A SG10201604497U A SG 10201604497UA SG 10201604497U A SG10201604497U A SG 10201604497UA
- Authority
- SG
- Singapore
- Prior art keywords
- cancer
- diagnostic test
- molecular diagnostic
- molecular
- test
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7014—(Neo)vascularisation - Angiogenesis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161492488P | 2011-06-02 | 2011-06-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201604497UA true SG10201604497UA (en) | 2016-07-28 |
Family
ID=47259970
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201604497UA SG10201604497UA (en) | 2011-06-02 | 2012-06-04 | Molecular Diagnostic Test For Cancer |
SG2013088216A SG195208A1 (en) | 2011-06-02 | 2012-06-04 | Molecular diagnostic test for cancer |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2013088216A SG195208A1 (en) | 2011-06-02 | 2012-06-04 | Molecular diagnostic test for cancer |
Country Status (13)
Country | Link |
---|---|
US (1) | US10260097B2 (en) |
EP (1) | EP2715348B1 (en) |
JP (2) | JP6067686B2 (en) |
KR (1) | KR20140044341A (en) |
CN (1) | CN103733065B (en) |
AU (1) | AU2012261820B2 (en) |
BR (1) | BR112013031019A2 (en) |
CA (1) | CA2838086A1 (en) |
EA (2) | EA025926B1 (en) |
IL (1) | IL229681A0 (en) |
MX (1) | MX2013014065A (en) |
SG (2) | SG10201604497UA (en) |
WO (1) | WO2012167278A1 (en) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112013031019A2 (en) | 2011-06-02 | 2017-03-21 | Almac Diagnostics Ltd | molecular diagnostic test for cancer |
EP2667193A1 (en) * | 2012-05-23 | 2013-11-27 | Université d'Aix-Marseille | MMP2 as a predictive biomarker of response to antiangiogenic therapy and survival after therapy in cancer patients |
WO2014055398A1 (en) * | 2012-10-05 | 2014-04-10 | Siemens Healthcare Diagnostics Inc. | Method for detecting an increased risk or incidence of colorectal cancer |
CA2893033A1 (en) * | 2012-12-03 | 2014-06-12 | Almac Diagnostics Limited | Molecular diagnostic test for cancer |
GB201313342D0 (en) * | 2013-07-26 | 2013-09-11 | Cancer Rec Tech Ltd | Biomarkers |
US10617755B2 (en) | 2013-08-30 | 2020-04-14 | Genentech, Inc. | Combination therapy for the treatment of glioblastoma |
US10456470B2 (en) | 2013-08-30 | 2019-10-29 | Genentech, Inc. | Diagnostic methods and compositions for treatment of glioblastoma |
GB201409479D0 (en) * | 2014-05-28 | 2014-07-09 | Almac Diagnostics Ltd | Molecular diagnostic test for cancer |
GB201409478D0 (en) * | 2014-05-28 | 2014-07-09 | Almac Diagnostics Ltd | Pro-angiogenic signature |
GB201409476D0 (en) * | 2014-05-28 | 2014-07-09 | Almac Diagnostics Ltd | Molecular subtype for use in prognosis |
CN106460067A (en) * | 2014-07-14 | 2017-02-22 | 豪夫迈·罗氏有限公司 | Diagnostic methods and compositions for treatment of glioblastoma |
KR20160101706A (en) * | 2015-02-17 | 2016-08-25 | 싸이퍼롬, 인코퍼레이티드 | Method for personalized prevention of adverse drug reaction of tocolytics based on information of individual deleterious protein sequence variation |
CN105160208A (en) * | 2015-05-29 | 2015-12-16 | 杭州奥视图像技术有限公司 | Clustering method based on network for disease subtype problem |
GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
MY191654A (en) | 2015-07-01 | 2022-07-05 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
US10650325B2 (en) * | 2015-07-31 | 2020-05-12 | Microsoft Technology Licensing, Llc | Deterministic message distribution |
EP3359692A4 (en) | 2015-10-05 | 2019-05-01 | Cedars-Sinai Medical Center | Method of classifying and diagnosing cancer |
CA3012060A1 (en) * | 2016-01-25 | 2017-08-03 | Sanofi | Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer by measuring the level of a plasma biomarker |
US20190127805A1 (en) * | 2016-03-15 | 2019-05-02 | Almac Diagnostics Limited | Gene signatures for cancer detection and treatment |
WO2018124153A1 (en) | 2016-12-28 | 2018-07-05 | 公益財団法人がん研究会 | Biomarker for predicting therapeutic effect of anti-vegfr-2 antibody drug, screening method, and screening kit |
CN107037210A (en) * | 2017-04-05 | 2017-08-11 | 北京蛋白质组研究中心 | Application of the THBS2 Protein Detections thing in diagnosis of hepatoma kit is prepared |
WO2018213331A1 (en) * | 2017-05-16 | 2018-11-22 | Lankenau Institute For Medical Research | Compositions comprising ligands to rhob protein and the uses thereof |
JP6776464B2 (en) | 2017-06-13 | 2020-10-28 | ボストンジーン コーポレイションBostonGene Corporation | Systems and methods for identifying cancer treatments from normalized biomarker scores |
US20180365372A1 (en) * | 2017-06-19 | 2018-12-20 | Jungla Inc. | Systems and Methods for the Interpretation of Genetic and Genomic Variants via an Integrated Computational and Experimental Deep Mutational Learning Framework |
EP3461915A1 (en) | 2017-10-02 | 2019-04-03 | Koninklijke Philips N.V. | Assessment of jak-stat1/2 cellular signaling pathway activity using mathematical modelling of target gene expression |
EP3502279A1 (en) | 2017-12-20 | 2019-06-26 | Koninklijke Philips N.V. | Assessment of mapk-ap 1 cellular signaling pathway activity using mathematical modelling of target gene expression |
WO2019165366A1 (en) * | 2018-02-23 | 2019-08-29 | Beth Israel Deaconess Medical Center | Drug efficacy evaluations |
AU2019253118B2 (en) * | 2018-04-13 | 2024-02-22 | Freenome Holdings, Inc. | Machine learning implementation for multi-analyte assay of biological samples |
CN113321647A (en) | 2018-06-15 | 2021-08-31 | 汉达癌症医药责任有限公司 | Salts of kinase inhibitors and compositions thereof |
EP3814014A2 (en) * | 2018-06-27 | 2021-05-05 | Qcdx, Llc | Biological sample holder and handler |
CN109585011A (en) * | 2018-10-26 | 2019-04-05 | 朱海燕 | The Illnesses Diagnoses method and machine readable storage medium of chest pain patients |
EP3880848A4 (en) * | 2018-11-14 | 2022-07-27 | Beyondspring Pharmaceuticals, Inc. | Methods of treating cancer using tubulin binding agents |
EP4004927A4 (en) * | 2019-07-22 | 2023-08-02 | Mission Bio, Inc. | Using machine learning to optimize assays for single cell targeted dna sequencing |
KR102289533B1 (en) * | 2019-08-19 | 2021-08-17 | 주식회사 테라젠바이오 | Device, method and computer program of determining genes related to the target gene based on the signature related to the target gene of a specific drug |
CN116312814A (en) * | 2021-12-02 | 2023-06-23 | 复旦大学 | Construction method, equipment, device and kit of lung adenocarcinoma molecular typing model |
CN116863995B (en) * | 2023-08-29 | 2024-05-14 | 北京大学第一医院 | Application of ALPK2, ITGA11, ESYT, CDH17 in prediction of drug bleeding |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5525464A (en) | 1987-04-01 | 1996-06-11 | Hyseq, Inc. | Method of sequencing by hybridization of oligonucleotide probes |
US5202231A (en) | 1987-04-01 | 1993-04-13 | Drmanac Radoje T | Method of sequencing of genomes by hybridization of oligonucleotide probes |
GB8810400D0 (en) | 1988-05-03 | 1988-06-08 | Southern E | Analysing polynucleotide sequences |
US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
US5547839A (en) | 1989-06-07 | 1996-08-20 | Affymax Technologies N.V. | Sequencing of surface immobilized polymers utilizing microflourescence detection |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
EP0430881A3 (en) | 1989-11-29 | 1991-10-23 | Ciba-Geigy Ag | Photochromic compounds, process for their preparation and their use |
US5288644A (en) | 1990-04-04 | 1994-02-22 | The Rockefeller University | Instrument and method for the sequencing of genome |
US5324633A (en) | 1991-11-22 | 1994-06-28 | Affymax Technologies N.V. | Method and apparatus for measuring binding affinity |
ATE173767T1 (en) | 1992-04-03 | 1998-12-15 | Perkin Elmer Corp | SAMPLES COMPOSITION AND METHODS |
US5503980A (en) | 1992-11-06 | 1996-04-02 | Trustees Of Boston University | Positional sequencing by hybridization |
US5858659A (en) | 1995-11-29 | 1999-01-12 | Affymetrix, Inc. | Polymorphism detection |
US5470710A (en) | 1993-10-22 | 1995-11-28 | University Of Utah | Automated hybridization/imaging device for fluorescent multiplex DNA sequencing |
GB9401833D0 (en) | 1994-02-01 | 1994-03-30 | Isis Innovation | Method for discovering ligands |
US6946442B2 (en) | 1994-11-30 | 2005-09-20 | Asif Syed Ahmed | Method of hastening cervical ripening |
GB9507238D0 (en) | 1995-04-07 | 1995-05-31 | Isis Innovation | Detecting dna sequence variations |
US5661028A (en) | 1995-09-29 | 1997-08-26 | Lockheed Martin Energy Systems, Inc. | Large scale DNA microsequencing device |
JP2002515738A (en) | 1996-01-23 | 2002-05-28 | アフィメトリックス,インコーポレイティド | Nucleic acid analysis |
US6680175B2 (en) * | 1998-05-05 | 2004-01-20 | Adherex Technologies, Inc. | Methods for diagnosing and evaluating cancer |
US6998234B2 (en) * | 2000-11-03 | 2006-02-14 | Oncotech, Inc. | Methods for cancer prognosis and diagnosis relating to tumor vascular endothelial cells |
US20030215424A1 (en) | 2002-05-15 | 2003-11-20 | Seul Kyung Hwan | Method of modulating angiogenesis |
AU2003281325A1 (en) | 2002-07-02 | 2004-01-23 | The Johns Hopkins University | Secreted and cytoplasmic tumor endothelial markers |
ME00425B (en) * | 2003-05-30 | 2011-10-10 | Genentech Inc | Treatment with anti-vegf antibodies |
US7659062B2 (en) | 2003-06-03 | 2010-02-09 | The Board of Trustee of the University of Arkansas System | Gene expression profiling of uterine serous papillary carcinomas and ovarian serous papillary tumors |
WO2005066371A2 (en) | 2003-12-31 | 2005-07-21 | The Penn State Research Foundation | Methods for predicting and overcoming resistance to chemotherapy in ovarian cancer and for predicting colon cancer occurrence |
US20080113874A1 (en) * | 2004-01-23 | 2008-05-15 | The Regents Of The University Of Colorado | Gefitinib sensitivity-related gene expression and products and methods related thereto |
EP2947160B1 (en) * | 2004-04-09 | 2017-07-12 | Genomic Health, Inc. | Gene expression markers for predicting response to chemotherapy |
MXPA06013079A (en) * | 2004-05-14 | 2007-10-08 | Ludwig Inst Cancer Res | Identification and characterization of a subset of glioblastomas sensitive to treatment with imatinib. |
AU2005263972A1 (en) * | 2004-07-23 | 2006-01-26 | Astrazeneca Ab | Method of predicting the responsiveness of a tumor to erbB receptor drugs |
EP1815021A2 (en) | 2004-11-03 | 2007-08-08 | Almac Diagnostics Limited | Transcriptome microarray technology and methods of using the same |
US7862995B2 (en) | 2004-12-10 | 2011-01-04 | Targeted Molecular Diagnostics | Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor |
US8093011B2 (en) | 2005-03-16 | 2012-01-10 | Haley John D | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
US20080305962A1 (en) * | 2005-07-29 | 2008-12-11 | Ralph Markus Wirtz | Methods and Kits for the Prediction of Therapeutic Success, Recurrence Free and Overall Survival in Cancer Therapies |
CA2623125A1 (en) | 2005-09-20 | 2007-03-29 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
US8445198B2 (en) * | 2005-12-01 | 2013-05-21 | Medical Prognosis Institute | Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
WO2007067476A2 (en) * | 2005-12-05 | 2007-06-14 | Merck & Co., Inc. | Methods for predicting treatment response based on the expression profiles of protein and transcription biomakers |
WO2007067500A2 (en) * | 2005-12-05 | 2007-06-14 | Genomic Health, Inc. | Predictors of patient response to treatment with egfr inhibitors |
CA2637446A1 (en) | 2006-01-27 | 2007-08-09 | Tripath Imaging, Inc. | Methods for identifying patients with an increased likelihood of having ovarian cancer and compositions therefor |
US20090275633A1 (en) | 2006-04-13 | 2009-11-05 | Oncomethylome Sciences Sa | Novel Tumour Suppressor |
US8768629B2 (en) * | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
SG174826A1 (en) | 2006-09-19 | 2011-10-28 | Novartis Ag | Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors |
CN101821406A (en) | 2007-08-13 | 2010-09-01 | 阿尔马科诊断有限公司 | 3' -based sequencing approach for microarray manufacture |
US20090092603A1 (en) * | 2007-09-25 | 2009-04-09 | Bamdad Cynthia C | Early diagnosis and treatment of drug resistance in muc1-positive cancer |
NZ562237A (en) | 2007-10-05 | 2011-02-25 | Pacific Edge Biotechnology Ltd | Proliferation signature and prognosis for gastrointestinal cancer |
EP2222874A2 (en) * | 2007-11-09 | 2010-09-01 | Genentech, Inc. | Methods and compositions for diagnostic use in cancer patients |
EP2242852A4 (en) * | 2007-12-07 | 2011-02-09 | Univ Oregon Health & Science | Methods to determine if a subject will respond to a bcr-abl inhibitor |
US8114593B2 (en) * | 2008-03-12 | 2012-02-14 | University Of Medicine And Dentistry Of New Jersey | Cancer biomarker genes and gene products and methods for using the same |
WO2009149297A1 (en) * | 2008-06-04 | 2009-12-10 | The Arizona Board Regents, On Behalf Of The University Of Arizona | Diffuse large b-cell lymphoma markers and uses therefor |
EP2294420B8 (en) * | 2008-06-06 | 2015-10-21 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Survival predictor for diffuse large B cell lymphoma |
CN102159727A (en) * | 2008-07-16 | 2011-08-17 | 达纳-法伯癌症研究院有限公司 | Signatures and pcdeterminants associated with prostate cancer and methods of use thereof |
WO2010010153A1 (en) * | 2008-07-23 | 2010-01-28 | F. Hoffmann-La Roche Ag | Identification of subjects being susceptible to anti-angiogenesis therapy |
WO2010072348A1 (en) | 2008-12-23 | 2010-07-01 | Merck Patent Gmbh | Biomarkers for inhibitors with anti-angiogenic activity |
WO2010088688A2 (en) | 2009-02-02 | 2010-08-05 | Biotheranostics, Inc. | Diagnosis of in situ and invasive breast cancer |
SG175832A1 (en) | 2009-05-01 | 2011-12-29 | Genomic Health Inc | Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy |
US7615353B1 (en) * | 2009-07-06 | 2009-11-10 | Aveo Pharmaceuticals, Inc. | Tivozanib response prediction |
CN102612566B (en) | 2009-09-17 | 2016-02-17 | 霍夫曼-拉罗奇有限公司 | For the method and composition of diagnostics purposes in cancer patients |
NZ620799A (en) | 2010-09-15 | 2015-10-30 | Almac Diagnostics Ltd | Molecular diagnostic test for cancer |
WO2012052757A1 (en) | 2010-10-20 | 2012-04-26 | Astrazeneca Ab | Tumour phenotype patient selection method |
EP2659005A4 (en) | 2010-12-28 | 2016-08-24 | Caris Mpi Inc | Molecular profiling for cancer |
BR112013031019A2 (en) | 2011-06-02 | 2017-03-21 | Almac Diagnostics Ltd | molecular diagnostic test for cancer |
RU2659173C2 (en) | 2012-01-13 | 2018-06-28 | Дженентек, Инк. | Biological markers for identifying patients for treatment with vegf antagonists |
EP2667193A1 (en) | 2012-05-23 | 2013-11-27 | Université d'Aix-Marseille | MMP2 as a predictive biomarker of response to antiangiogenic therapy and survival after therapy in cancer patients |
CA2893033A1 (en) | 2012-12-03 | 2014-06-12 | Almac Diagnostics Limited | Molecular diagnostic test for cancer |
-
2012
- 2012-06-04 BR BR112013031019A patent/BR112013031019A2/en not_active IP Right Cessation
- 2012-06-04 SG SG10201604497UA patent/SG10201604497UA/en unknown
- 2012-06-04 WO PCT/US2012/040805 patent/WO2012167278A1/en active Application Filing
- 2012-06-04 KR KR1020137034588A patent/KR20140044341A/en not_active Application Discontinuation
- 2012-06-04 MX MX2013014065A patent/MX2013014065A/en unknown
- 2012-06-04 EP EP12793609.4A patent/EP2715348B1/en active Active
- 2012-06-04 AU AU2012261820A patent/AU2012261820B2/en not_active Ceased
- 2012-06-04 EA EA201391805A patent/EA025926B1/en not_active IP Right Cessation
- 2012-06-04 SG SG2013088216A patent/SG195208A1/en unknown
- 2012-06-04 CA CA2838086A patent/CA2838086A1/en not_active Abandoned
- 2012-06-04 CN CN201280037298.2A patent/CN103733065B/en not_active Expired - Fee Related
- 2012-06-04 JP JP2014513800A patent/JP6067686B2/en not_active Expired - Fee Related
- 2012-06-04 US US14/123,406 patent/US10260097B2/en not_active Expired - Fee Related
- 2012-06-04 EA EA201691257A patent/EA201691257A1/en unknown
-
2013
- 2013-11-28 IL IL229681A patent/IL229681A0/en unknown
-
2016
- 2016-12-21 JP JP2016248061A patent/JP2017079772A/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
CN103733065A (en) | 2014-04-16 |
EA201391805A1 (en) | 2014-03-31 |
AU2012261820B2 (en) | 2017-01-19 |
SG195208A1 (en) | 2013-12-30 |
EA025926B1 (en) | 2017-02-28 |
IL229681A0 (en) | 2014-01-30 |
CA2838086A1 (en) | 2012-12-06 |
US20140342924A1 (en) | 2014-11-20 |
US10260097B2 (en) | 2019-04-16 |
CN103733065B (en) | 2017-12-15 |
EP2715348A4 (en) | 2015-10-07 |
EP2715348B1 (en) | 2019-04-10 |
EA201691257A1 (en) | 2017-02-28 |
JP2014516552A (en) | 2014-07-17 |
WO2012167278A1 (en) | 2012-12-06 |
KR20140044341A (en) | 2014-04-14 |
EP2715348A1 (en) | 2014-04-09 |
NZ618191A (en) | 2015-04-24 |
JP6067686B2 (en) | 2017-01-25 |
JP2017079772A (en) | 2017-05-18 |
MX2013014065A (en) | 2014-06-23 |
BR112013031019A2 (en) | 2017-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1214633A1 (en) | Molecular diagnostic test for cancer | |
IL229681A0 (en) | Molecular diagnostic test for cancer | |
ZA201508689B (en) | Molecular diagnostic test for cancer | |
IL244472A0 (en) | Molecular diagnostic test for lung cancer | |
EP2585833A4 (en) | Methods for detecting cancer | |
EP2776831A4 (en) | Paper based diagnostic test | |
GB201105474D0 (en) | Testing apparatus | |
PT2829881T (en) | Diagnostic for colorectal cancer | |
EP2705366A4 (en) | Diagnostic device | |
EP2737315A4 (en) | Cartridge for diagnostic testing | |
EP2783627A4 (en) | Diagnostic device | |
ZA201402224B (en) | Diagnostic apparatus | |
EP2748608A4 (en) | Lung cancer tests | |
IL244471A0 (en) | Molecular diagnostic test for oesophageal cancer | |
EP2524702A4 (en) | Diagnostic for cancer | |
GB201012590D0 (en) | Methods for diagnosing cancer | |
GB201008541D0 (en) | Diagnostic methods | |
EP2692275A4 (en) | Diagnostic system | |
EP2870499A4 (en) | Diagnostic apparatus | |
GB2489262B (en) | Testing apparatus | |
EP2742358A4 (en) | Methods for diagnosing cancer | |
AU342348S (en) | Testing apparatus | |
AP2013008332A0 (en) | Diagnostic probe | |
EP2661625A4 (en) | Diagnostic methods | |
GB201110712D0 (en) | Diagnostic methods |